This week, the financing heat in the medical and health field has risen, covering cutting-edge tracks such as CGT upstream reagents, digestive endoscopic surgical robots, ultrasound thrombolysis, immunotherapy, in situ differentiation, and inflammatory immunity. Spolikang is making efforts to replace CGT domestically, Robb Medical is accelerating the commercialization of surgical robots, Newlyjet is leading in in-situ differentiation technology globally, and Aikono and Yirui Medicine are deeply involved in the field of self exemption. Capital is accelerating towards hard tech enterprises with breakthroughs in underlying technologies and clinical scarcity value, demonstrating the vitality of the medical innovation ecosystem.

---

1、 Bolikang completes nearly 100 million yuan Series A financing and focuses on domestic substitution of CGT upstream reagents

Recently, Spolikang, which focuses on the research and development of upstream core reagents and CRDMO services in the field of cell and gene therapy (CGT), announced the completion of nearly 100 million yuan in Series A financing. This round is led by Jincheng Fund, a subsidiary of Luzhou Development Holdings Group, with follow-up investment from Qingke Industrial Investment and joint investment from existing shareholders. Shengke Pharmaceutical Capital serves as the exclusive financial advisor. The financing funds will mainly be used for the expansion of CGT’s core reagent production capacity, the establishment of new regional business subsidiaries, the iteration of core technology research and development, and the promotion of domestic and foreign markets.

The current domestic biopharmaceutical upstream reagent market continues to expand, and CGT is one of the fastest-growing segments in the industry. With the domestic CGT industry entering a period of commercial explosion, there is an urgent need for domestic substitution of upstream core reagents. At present, there are no domestic leading enterprises with scale competitiveness in this track, and there is a large gap in the supply side. The growth space for top players is vast.

Established in 2023, Spolikang has built an integrated business model of “reagents+processes+services”, relying on a research and development platform with independent intellectual property rights to build a complete product pipeline of multiple categories. The core product performance has reached the international level of similar products. At present, the company’s products have entered several leading CGT pharmaceutical companies and top research institutions in China, and have also achieved mass export overseas, with commercial implementation progress exceeding expectations.

After this round of financing, Spolikang will accelerate the expansion of its GMP level large-scale production system, accelerate the layout of its full category product business, continue to increase investment in core technology research and development, further expand its overseas commercial network, and create a locally competitive CGT upstream core supplier with global competitiveness.

---

2、 Robb Medical has completed a B+round financing of tens of millions of yuan, accelerating the commercialization of digestive endoscopic surgical robots

Recently, Shenzhen Robb Medical Technology Co., Ltd. announced the completion of a B+round financing of tens of millions of yuan. This round is led by Shuimu Venture Capital, with Boyue Tiancheng as the co investor and Siche Consulting as the exclusive financial advisor. The raised funds will be used for the nationwide clinical commercialization of core products, research and development of next-generation surgical robot platforms, construction of operation training bases and supply chain optimization, as well as international market access promotion, to accelerate the commercialization process of digestive endoscopic surgical robots.

As the world’s first digestive endoscopic surgical robot enterprise approved for listing, Robb Medical’s current round of financing coincides with the industry’s policy dividend window: in January 2026, the National Healthcare Security Administration officially introduced the surgical robot fee policy, clarifying the rules for robot assisted surgery fees, and breaking through the payment barriers for large-scale commercialization of surgical robots. Enterprises with first mover access advantages are the first to benefit. As of now, Rob Medical’s core product EndoFaster has completed product access in 31 provincial-level administrative regions across the country, and its commercialization progress is leading the domestic market.

In terms of clinical value, EndoFaster can effectively reduce the risk of bleeding and perforation complications in minimally invasive resection surgery of digestive endoscopy, significantly shorten the operator’s learning curve, and its technical advantages have been recognized by top academic institutions in the international digestive endoscopy field, laying the foundation for global expansion. The current global penetration rate of minimally invasive digestive endoscopy surgery continues to increase, and players in the surgical robot track are accelerating their layout. With the advantage of first mover approval and a complete commercial layout, Robb Medical is expected to quickly seize the core share of the segmented track.

---

3、 Xinhong Life has received Series A financing to build an innovative ultrasound ecosystem

Recently, Xinhong Life, a domestic innovative ultrasound energy device platform, announced the completion of tens of millions of RMB in Series A financing. This round of financing is exclusively led by Yifeng Zhuohua Fund, a subsidiary of Yifeng Capital. The funds will be used to promote the commercialization of core ultrasound thrombectomy products and accelerate the construction of an innovative ultrasound ecosystem with “ultrasound energy, drug sound collaboration, and precise diagnosis and treatment” throughout the entire chain.

Venous thromboembolism (VTE) is the third largest vascular emergency in the world. The overall incidence of VTE in hospitalized patients in China exceeds 13%. Among them, acute mixed/subacute, and chronic deep vein thrombosis (DVT) closely adheres to the vascular wall after thrombus organization. Traditional catheter thrombolysis and surgical thrombectomy generally have pain points of high bleeding risk and incomplete thrombus clearance, and there is a clear unmet need in clinical practice. Ultrasound thrombolysis, with its technological advantages of low trauma and low bleeding risk, is widely recognized as the core direction for solving the problem of mixed thrombus clearance, and is currently one of the most promising frontiers in the field of thrombus intervention devices.

The integrated multi-directional pulse ultrasound thrombectomy system independently developed by Xinhong Life is one of the few original products in the domestic market that has been promoted to the market stage. It has completed all registered clinical studies and has been approved for the special review of innovative medical devices by the National Medical Products Administration (Green Channel). It is currently in the stage of market review. The leading investor of Yifeng Zhuohua Fund stated that Xinhong Life Technology has outstanding innovation, strong commercial certainty of core products, and platform based technology can be expanded to multiple disease fields, with broad long-term growth space.

---

4、 Bodi Hekang completes Series A financing, with Fudan Sci Tech Innovation and Longpan Investment jointly leading the investment

Domestic innovative immunotherapy company Bodihekang recently completed its Series A financing, led by Fudan Sci Tech Innovation and Longpan Investment. The funding will be used to advance the Phase I clinical trial of the core pipeline BT-101, as well as preclinical research on multiple cell therapy pipelines, accelerating the clinical translation and implementation of original immune tolerance reconstruction therapy.

Bodihekang was founded in 2021, focusing on the urgent clinical needs of autoimmune and inflammatory diseases. Its core technology comes from the basic research accumulation of regulatory T cell (Treg) mechanisms by the Shi Yan team at Fudan University over the past 20 years. Two original technology platforms have been built around the precise regulation logic of Treg, and a full stage multi pipeline layout from innovative drugs to cell therapy has been constructed. At present, the company’s core pipeline BT-101 has obtained IND licenses from both China and the United States, and is about to start human clinical trials. The BT-201 and BT-202 cell therapy pipelines are also advancing preclinical development simultaneously.

The global scale of autoimmune disease patients exceeds 400 million, and the domestic patient population exceeds 10 million. Traditional treatment mainly relies on non-specific immune suppression, which has shortcomings such as long-term medication side effects and inability to achieve root cause relief of the disease. Clinical unmet needs are extremely prominent. Bodi Hekang’s differentiated route from immune tolerance reconstruction to Treg track has gained recognition from industrial capital and is expected to rewrite the existing pattern of self immune disease treatment.

---

5、 NewlyJet completes Series A financing, from Optics Valley to Global

On May 20th, Wuhan New Lunjie Biopharmaceutical Technology Co., Ltd. announced the completion of its Series A financing, led by Wuhan Optics Valley Science and Technology Innovation Industry Investment Fund and followed by Zhuhai Hengqin Soft Silver Xinchuang; Combined with the previous Pre-A+round of additional investment, the company has raised nearly 100 million yuan in cumulative financing for 2025, which is a representative financing event in the field of differentiated innovation in the Huazhong life and health track.

Newgene was founded by a core team from the Chinese Academy of Sciences, focusing on the development of a new generation of in situ differentiation technology. This technology does not require in vitro stem cell editing or allogeneic transplantation, and can directly reprogram in situ cells into functional cells in vivo, avoiding the immune rejection and tumorigenic risks of traditional cell gene therapy, with prominent technical barriers. The core support for the smooth progress of this round of financing is the global regulatory breakthrough of the company’s core pipeline: NRG-103 injection is the world’s first in situ tumor gene therapy to receive formal clinical trial approval from the FDA. It has now advanced to the stage of dual reporting between China and the United States, and its technical value and development progress have been recognized by global regulatory authorities.

At present, the company has laid out a clear gradient R&D pipeline in the fields of cancer, ophthalmology, neurodegenerative diseases and other major indications around the core technology platform. The financing funds will be used for the promotion of core pipeline clinical trials, early pipeline pre clinical research and development and core technology platform iteration. Relying on the empowerment of Wuhan Optics Valley life health industry cluster, Nulunjie is moving from its local innovation base to the global market, and has also opened up a new direction of differentiated innovation for the domestic cell gene therapy track.

---

6、 Aikono Biopharmaceuticals completes $50 million Series C financing to advance research and development in inflammatory and immune diseases

Recently, the innovative pharmaceutical company Aikono Biopharmaceuticals, which focuses on the field of regulatory cell death, officially announced the completion of a $50 million Series C financing. This round of financing is led by the world’s leading healthcare investment institution, Aobo Capital, TCGX、 Renowned industry investment institutions such as Eli Lilly Asia Fund jointly participate in the investment.

The proceeds from this round of financing will be primarily used to advance the Phase IIb clinical trial of the core pipeline AC-101 for the treatment of ulcerative colitis (UC), while accelerating the company’s overall development process for inflammatory and immune disease pipelines. AC-101 is a differentiated candidate drug independently developed by Aikono, which is a novel highly selective oral small molecule inhibitor of RIPK2. RIPK2, as the core mediator molecule of the NOD1/2 signaling pathway, is a popular target for autoimmune diseases such as inflammatory bowel disease and ankylosing spondylitis, and can block the activation of the inflammatory cascade from the source. At present, AC-101 has completed Phase I clinical trials, with preliminary verification of safety and pharmacokinetic characteristics, and has obtained FDA approval to advance the development of Phase II indications for UC.

This financing has received support from top institutions, which not only reflects the value recognition of the primary market for the unmet demand of innovative drugs for inflammation and immunity, but also confirms the industry’s recognition of the layout and pipeline potential of the Aikono circuit. The leading investor, Aobo Capital, is a globally leading healthcare investment institution with assets under management exceeding $19 billion. It has long been deeply involved in the innovative biopharmaceutical field.

---

7、 Yirui Pharmaceutical has secured a billion yuan Series A++financing

Hangzhou Yirui Pharmaceutical Technology Co., Ltd. recently completed a billion yuan A++round of financing. This round of financing is jointly funded by multiple industry investment institutions deeply involved in the biopharmaceutical field, and the capital support will further accelerate the global research and development process of the company’s differentiated innovation pipeline. The funds raised in this round of financing will be directed towards three main directions: advancing clinical trials in core pipelines, early innovative drug research and development reserves, and global layout implementation. Specifically, it will support domestic bridging trials of core varieties and global multi center IIb/III clinical research, promote the entry of the inflammatory bowel disease candidate drug YR-011 into phase I clinical trials, and accelerate the research and optimization of multiple preclinical candidate compounds.

Yirui Medicine focuses on the field of autoimmune diseases that do not meet clinical needs. The core pipeline YR-001 is a highly selective KV1.3 ion channel inhibitor that entered the clinical stage earlier in China and has obtained clinical research approval from the US FDA. Its differentiated First in class attribute is outstanding.

The current domestic autoimmune skin disease market has entered a period of rapid expansion. According to industry estimates, the market size of moderate to severe atopic dermatitis in China is expected to exceed 29 billion yuan by 2030. KV1.3 inhibitors, with the safety advantage of long-term use, are suitable for the long-term treatment needs of autoimmune chronic diseases, and there are very few innovative enterprises in China that have laid out this target, resulting in significant scarcity in the market. At present, the domestic self exemption track financing activity continues to be high, and differentiated pipelines with original potential are increasingly recognized by industrial capital. This financing also confirms the primary market’s preference for scarce innovative assets.

---

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.